← Leaderboards
Maria L Avantaggiati
Roswell Park Cancer Institute Corp
$6,905,214
Attributed
$6,905,214
Total exposure
8
Grants
7
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $597.1K · FY2005–24$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$6,905,214 · 8
By mechanism
R01$5,544,207 · 4
R21$1,205,007 · 3
R03$156,000 · 1
Top collaborators
No co-investigators on record.
Others in their field
Top investigators on “Apoptosis”
- David Heimbrook · Leidos Biomedical Research, Inc.$49,205,802
- Jay A Nelson · Oregon Health & Science University$45,942,124
- John C Reed · University Of Texas Md Anderson Can Ctr$34,437,189
- John A Tainer · Scripps Research Institute$30,637,655
- Henry Shelton Earp · Univ Of North Carolina Chapel Hill$28,872,594
- John D Minna · University Of Texas Sw Med Ctr/Dallas$27,317,167
Research focus
ApoptosisAcetylationPathway InteractionsCellsP53 Gene /ProteinPlayNeoplastic CellMolecularAffectAcyltransferaseLeadProteinsMalignant NeoplasmsBaseEnzyme ActivityResponseIn VivoSite Directed MutagenesisTumorCell CycleInhibitor/AntagonistMetabolicCitratesCitrate Carrier
Grant awards (28)
A novel murine model of 2-Hydroxyglutaric aciduria$156,000
R03 · FY2024 · TR · contact PI
Targeting the metabolic vulnerabilities of patient-derived drug resistant tumors$178,679
R21 · FY2022 · CA · contact PI
Targeting the metabolic vulnerabilities of patient-derived drug resistant tumors$218,790
R21 · FY2021 · CA · contact PI
Understanding the molecular alterations of diseases due to SLC25A1 deficiency$194,375
R21 · FY2020 · DE · contact PI
Role of the mitochondrial citrate carrier SLC25A1(CIC)in cancer progression and therapy$345,034
R01 · FY2019 · CA · contact PI
Understanding the molecular alterations of diseases due to SLC25A1 deficiency$233,250
R21 · FY2019 · DE · contact PI
Role of the mitochondrial citrate carrier SLC25A1(CIC)in cancer progression and therapy$355,706
R01 · FY2018 · CA · contact PI
Role of the mitochondrial citrate carrier SLC25A1(CIC)in cancer progression and therapy$355,706
R01 · FY2017 · CA · contact PI
Role of the mitochondrial citrate carrier SLC25A1(CIC)in cancer progression and therapy$355,706
R01 · FY2016 · CA · contact PI
Role of the mitochondrial citrate carrier SLC25A1(CIC)in cancer progression and therapy$355,706
R01 · FY2015 · CA · contact PI
Functional Mimicry of the p53 C-terminal Tail by the Ubiquitin-like Molecule SUMO$172,688
R21 · FY2009 · CA · contact PI
anti-tumor activity of deacetylase inhibitors$271,505
R01 · FY2008 · CA · contact PI
Functional Mimicry of the p53 C-terminal Tail by the Ubiquitin-like Molecule SUMO$207,225
R21 · FY2008 · CA · contact PI
anti-tumor activity of deacetylase inhibitors$271,505
R01 · FY2007 · CA · contact PI
Role of the Acetyltransferase p300 in Cellular Responses$303,484
R01 · FY2006 · CA · contact PI
anti-tumor activity of deactylase inhibitors$279,615
R01 · FY2006 · CA · contact PI
Role of the Acetyltransferase p300 in Cellular Responses$310,788
R01 · FY2005 · CA
anti-tumor activity of deactylase inhibitors$286,344
R01 · FY2005 · CA
Role of the Acetyltransferase p300 in Cellular Responses$304,380
R01 · FY2004 · CA
anti-tumor activity of deacetylase inhibitors$286,344
R01 · FY2004 · CA
ACETYLTRANSFERASES AND ONCOGENESIS$186,830
R01 · FY2003 · CA
Role of the Acetyltransferase p300 in Cellular Responses$173,857
R01 · FY2003 · CA
Role of the Acetyltransferase p300 in Cellular Responses$138,982
R01 · FY2003 · CA
ACETYLTRANSFERASES AND ONCOGENESIS$37,238
R01 · FY2003 · CA
Role of the Acetyltransferase p300 in Cellular Responses$310,788
R01 · FY2002 · CA
ACETYLTRANSFERASES AND ONCOGENESIS$210,041
R01 · FY2002 · CA
ACETYLTRANSFERASES AND ONCOGENESIS$205,314
R01 · FY2001 · CA
ACETYLTRANSFERASES AND ONCOGENESIS$199,334
R01 · FY2000 · CA